Fri, Sep 10 | Zoom Webinar

O2M Webinar: Periannan Kuppusamy, PhD, MD.

Phase I Clinical Trial Establishing the Feasibility and Potential Utility of EPR Oximetry using OxyChip for Repeated Measurements of Tumor Oxygen
O2M Webinar: Periannan Kuppusamy, PhD, MD.

Time

Sep 10, 11:00 AM – 12:00 PM CDT
Zoom Webinar

Details

Moderated by: TBA

About the Speaker: Dr. Kuppusamy is a tenured Professor in the Departments of Radiology and Medicine at

the Geisel School of Medicine, Dartmouth College. He received his PhD in 1986 from

the Indian Institute of Technology, Chennai, India. Following a 2-year Fogarty

Fellowship from NIH/NIA, he became a faculty in the Department of Medicine at the

Johns Hopkins University School of Medicine, in 1987. He then moved to the Ohio State

University in 2002, where he was holding the William D. and Jacquelyn L. Wells Chair

in Imaging Research. He also served as the Associate Director of the Division of

Cardiovascular Medicine. He joined the Geisel School of Medicine at Dartmouth College

in 2013. Dr. Kuppusamy’s research interests include free radicals, oxygen and oxygen

biology in cardiovascular diseases and cancer. He is well-known for his expertise in the

development of imaging methods for imaging oxygen and free radicals in biological

systems. Dr. Kuppusamy has received numerous research awards including Silver Medal

in 2006 from the International EPR Society for significant contribution to the

development of EPR imaging for biomedical applications and Doctor of Medicine

(honoris causa) in 2008 from University of Pecs (Pecs, Hungary) for cardiovascular

research. Dr. Kuppusamy has published 400 peer-reviewed research manuscripts in

leading biomedical journals. He has received several research grants from the American

Heart Association and National Institutes of Health. He has several patents on the probes

and methods for determination of oxygen concentration in tissues. One of his inventions,

OxyChip, is currently in a Phase I clinical trial.

About the Webinar: Clinical interventions to mitigate the impact of tumor hypoxia on cancer-treatment outcomes

have been hampered by an inability to assess patient-specific tumor oxygen levels. The

overall objective of this first-in-human study was to assess the safety and feasibility a novel

oxygen sensor, called ‘OxyChip’, as a clinically viable technology to make individualized

tissue-oxygen assessments. OxyChip is a paramagnetic oxygen sensor composed of oxygen-

sensing lithium octa-n-butoxynaphthalocyanine (LiNc-BuO) crystals embedded in a

biocompatible polymer. Patients with any tumor at ≤3-cm depth from the skin surface and

scheduled to receive surgical resection (with or without neoadjuvant therapy) were

considered eligible. OxyChips were implanted in the tumor and subsequently removed

during surgery. Oxygen (pO 2 ) at the sensor location was assessed using electron

paramagnetic resonance (EPR) oximetry. During each measurement session, the patient

breathed room air, followed by a period of oxygen inhalation using a non-rebreather mask

with 100% oxygen delivered at a flow rate of 15 l/min, and then breathed room air again.

Twenty-four patients underwent OxyChip implantation in their tumors. Six patients received

neoadjuvant therapy. Median implant duration was 29 days (range 4–128 days). The

OxyChips recovered from the patients did not show any significant change in their oxygen

sensitivity. The implantation procedure and the process of EPR oximetry in the clinic were

well tolerated by patients. Histopathologic findings revealed no clinically significant

pathology, indicating that the tissue reaction to the OxyChip was well within expectations for

an implanted device [1]. A total of 44 measurements were made in 15 patients. Baseline

tumor pO 2 was variable with overall median of 10.2 mmHg (range 0–48.5 mmHg); 48% of

the values were below clinically significant hypoxia (10 mmHg). After hyperoxygenation,

the overall median pO 2 was 21.4 mmHg (range 0.4–97.6 mmHg). For 61% of measurements,

there was a statistically significant (p<0.05) response to hyperoxygenation. Measurement of

baseline pO 2 and response to hyperoxygenation using EPR oximetry with OxyChip is

clinically feasible in a variety of tumor types. Tumor oxygenation at baseline also differed

significantly among patients, with about half exhibiting clinically significant hypoxia at

baseline. Although most tumors responded to hyperoxygenation intervention, some were

non-responders. The pO 2 data demonstrated the need for individualized assessment of tumor

oxygenation in the context of planned hyperoxygenation interventions to optimize clinical

outcomes.

Share This Event